To come up with the list, we considered only the stocks with more than $2 billion in market capitalization and $5 million in intraday trading volume. Tempus AI extended its winning streak for a ...

Shares of Tempus AI (NASDAQ: TEM) were skyrocketing 16.5% higher as of 10:39 a.m. ET on Wednesday. The big gain came after the healthcare artificial intelligence (AI) company announced a multiyear ...

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ultimately be used to develop new cancer drugs. Tempus will use its “vast ...

Tempus AI also announced a promising new partnership with AstraZeneca and Pathos AI to aid cancer research and treatment. Tempus AI could have an incredible runway for growth, but its valuation ...

Tempus AI is trading near yearly lows despite ... reported a quarter where revenue actually missed analyst targets by $2 million, but the company expects huge revenue growth in 2025 due to both ...

Tempus AI announces a multi-year collaboration with AstraZeneca and Pathos AI to build a multimodal foundation model in oncology. Tempus says the collaboration includes $200 million in data ...

To come up with the list, we considered only the stocks with more than $2 billion in market capitalization and $5 million in intraday trading volume. Tempus AI extended its winning streak for a third ...

a quick ratio of 2.55 and a current ratio of 2.69. Tempus AI has a 12-month low of $22.89 and a 12-month high of $91.45. A number of hedge funds have recently bought and sold shares of TEM.

Investors with a lot of money to spend have taken a bullish stance on Tempus AI TEM ... In the last month, 2 experts released ratings on this stock with an average target price of $65.0. Turn ...